Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.19.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2019
Jun. 30, 2019
Current assets:    
Cash $ 2,103 $ 4,421
Accounts receivable - trade 75 97
Prepaid expenses and other current assets 183 290
Total Current Assets 2,361 4,808
Finance lease right-of-use assets, net of accumulated amortization 28,862 0
Fixed assets, net of accumulated depreciation 2,594 24,380
Intangible assets, net of accumulated amortization 1,323 1,374
Security deposit 24 24
Total Assets 35,164 30,586
Current liabilities:    
Accounts payable (related party of $109 and $125 as of September 30, 2019 and June 30, 2019, respectively) 661 1,001
Accrued expenses (related party of $846 and $699 as of September 30, 2019 and June 30, 2019, respectively) 1,175 965
Finance lease obligation - current portion 139 0
Capital lease obligation - current portion 0 213
Contract liabilities 2,894 1,279
Total Current Liabilities 4,869 3,458
Finance lease obligation - non-current portion 32,235 0
Capital lease obligation - net of current portion 0 24,671
Total Liabilities 37,104 28,129
Commitments and Contingencies
iBio, Inc. Stockholders' Equity (Deficiency):    
Preferred Stock, Value, Issued 0 0
Common stock - $0.001 par value; 275,000,000 shares authorized; 24,152,455 and 20,152,458 shares issued and outstanding as of September 30, 2019 and June 30, 2019, respectively 24 20
Additional paid-in capital 108,359 108,295
Accumulated other comprehensive loss (32) (31)
Accumulated deficit (110,284) (105,821)
Total iBio, Inc. Stockholders' Equity (Deficiency) (1,933) 2,463
Noncontrolling interest (7) (6)
Total Equity (Deficiency) (1,940) 2,457
Total Liabilities and Equity (Deficiency) 35,164 30,586
Series A Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity (Deficiency):    
Preferred Stock, Value, Issued 0 0
Series B Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity (Deficiency):    
Preferred Stock, Value, Issued $ 0 $ 0